Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2021 | Myeloma: elranatamab mechanism of action

Alexander Lesokhin • 19 Apr 2021
IMS 2021
Multiple Myeloma Antibodies Elranatamab

Alexander Lesokhin, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the mechanism of action of elranatamab (PF-06863135), designed for patients with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody that binds to two antigens, CD3 on T-cells and B-cell maturation antigen (BCMA), which is highly expressed on multiple myeloma cells and essential for myeloma cell survival. By bringing T-cells and cancer cells in close proximity, elranatamab can activate T-cells to kill cancer cells. This interview took place during the 2nd Immune Effector Cell Therapy in MM Workshop in Boston, MA.

More from Alexander Lesokhin

1:33
The potential role of belantamab mafodotin in multiple myeloma
Alexander Lesokhin • 10 Dec 2022
1:00
Highlights at ASH 2022: the promise of T-cell redirecting therapies in multiple myeloma
Alexander Lesokhin • 10 Dec 2022
3:44
Can diet impact treatment outcomes and progression of patients with multiple myeloma?
Alexander Lesokhin • 10 Dec 2022
2:31
Evaluating the safety of maintenance therapy cessation in MRD negative myeloma patients
Alexander Lesokhin • 10 Dec 2022

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals